Research Article
Clinical Characteristics of Patients with Different N-Terminal Probrain Natriuretic Peptide Levels after Hematopoietic Stem Cell Transplantation
Table 2
In-hospital transplantation-related parameters.
| | Variables | Total () | ENPH () | ENAH () | NN () | value |
| | Diagnosis | | | | | | | Acute lymphoblastic leukemia | 107 (35.5) | 16 (23.2) | 70 (42.7) | 21 (30.9) | 0.012 | | Acute myeloid leukemia | 130 (43.2) | 36 (52.2) | 62 (37.8) | 32 (47.1) | 0.099 | | Othera | 64 (21.3) | 17 (24.6) | 32 (19.5) | 15 (22.1) | 0.672 | | Transplant type | | | | | 0.033 | | Autologous HSCT | 42 (14.0) | 7 (10.1) | 19 (11.6) | 16 (23.5) | | | Allogeneic HSCT | 259 (86.0) | 62 (89.9) | 145 (88.4) | 52 (76.5) | | | Donor type | | | | | | HLA matched, related | 119 (39.5) | 22 (31.9) | 63 (38.4) | 34 (50.0) | 0.087 | | HLA partially matched, related | 99 (32.9) | 32 (46.4) | 56 (34.1) | 11 (16.2) | 0.001 | | HLA matched, unrelated | 30 (10.0) | 4 (5.8) | 19 (11.6) | 7 (10.3) | 0.402 | | Stem cell source | | | | | <0.001 | | Peripheral blood | 198 (65.8) | 37 (53.6) | 101 (61.6) | 60 (88.2) | | | Bone marrow+peripheral blood | 103 (34.2) | 32 (46.4) | 63 (38.4) | 8 (11.8) | | | Conditioning regimens | | | | | | | CY based | 267 (88.7) | 64 (92.8) | 152 (92.7) | 51 (75.0) | <0.001 | | Anthracycline based | 51 (16.9) | 14 (20.3) | 28 (17.1) | 9 (13.2) | 0.545 | | TBI based | 138 (45.8) | 25 (36.2) | 85 (51.8) | 28 (41.2) | 0.063 | | TBI+CY+VP-16/FA | 113 (37.5) | 23 (33.3) | 69 (42.1) | 21 (30.9) | 0.198 | | Prophylaxis regimens for GVHD | | | | | | | CsA+MTX±MMF | 110 (36.8) | 19 (27.9) | 63 (38.4) | 28 (41.8) | 0.202 | | CsA+MTX+ATG±MMF | 141 (47.2) | 40 (58.8) | 79 (48.2) | 22 (32.8) | 0.010 |
|
|
Values are , (%). ENPH: elevated NT-proBNP and presence of clinical symptoms or signs of heart failure; ENAH: elevated NT-proBNP but absence of symptoms or signs of heart failure; NN: normal NT-proBNP; HSCT: hematopoietic stem cell transplantation; HLA: human leukocyte antigen; CY: cyclophosphamide; TBI: total body irradiation; BU: busulfan; VP-16: etoposide; FA: fludarabine and cytarabine; GVHD: graft-versus-host disease; CsA: ciclosporin A; MTX: methotrexate; MFF: mycophenolate mofetil; ATG: antithymocyte globulin. aLymphoma ( ), myelodysplastic syndrome ( ), acute mixed lineage leukemia ( ), chronic myeloid leukemia ( ), biphenotypic acute leukemia ( ), etc. |
